ADHD
PBAC backs ADHD meds listing change
Changes to PBS restrictions for atomoxetine and guanfacine for the treatment of ADHD are being supported by the PBAC The Pharmaceutical Benefits Advisory Committee (PBAC) is backing a move to broaden access …
Methylphenidate shortage ‘resolving’: TGA
Global shortages of methylphenidate modified-release medications continue to improve and stabilise, regulator says Supply shortages of multiple strengths of medications used to treat attention deficit hyperactivity disorder (ADHD) are expected to be resolved by …
Clonidine 10-fold overdose in a paediatric patient due to a compounding error
Bryanna Gillies presents a case history report with important lessons about compounding A five-year-old boy presented to a tertiary paediatric emergency department on advice from the poisons centre, who received …
World news wrapup: 10 November 2022
New Zealand pharmacy leader calls for inappropriate prescribing crackdown; sentence reduced for Canadian pharmacist who faked robbery; pharmacist drowns providing health care New Zealand: A leading pharmacist has urged authorities …
‘New kids on the block’ pose fresh risks
Leading addiction specialist warns about emerging misuse of non-opioid prescription drugs including quetiapine, gabapentinoids and ADHD medicine There are some “golden oldies” that are familiar when it comes to pharmaceutical …
Imaging study confirms differences in ADHD brains
Imaging study confirms differences in ADHD brains Alison Poulton, University of Sydney The prestigious journal The Lancet has published a large study identifying differences in the brains of people diagnosed …